172 related articles for article (PubMed ID: 32002174)
21. Biosimilars in Dermatology - theory becomes reality.
Gerdes S; Mrowietz U; Augustin M; Ralph von Kiedrowski ; Enk A; Strömer K; Schön MP; Radtke MA
J Dtsch Dermatol Ges; 2018 Feb; 16(2):150-160. PubMed ID: 29364594
[TBL] [Abstract][Full Text] [Related]
22. Biosimilars in ulcerative colitis: When and for who?
Ilias A; Gonczi L; Kurti Z; Lakatos PL
Best Pract Res Clin Gastroenterol; 2018; 32-33():35-42. PubMed ID: 30060937
[TBL] [Abstract][Full Text] [Related]
23. A concept for multi-winner tenders for medicinal products with balancing between efficient prices, long-term competition and sustainability of supply.
Németh G; Mágó ML; Kaló Z; Lám J; Balogh T; Brodszky V
Front Med (Lausanne); 2023; 10():1282698. PubMed ID: 37964880
[TBL] [Abstract][Full Text] [Related]
24. The impact of pharmaceutical tendering on prices and market concentration in South Africa over a 14-year period.
Wouters OJ; Sandberg DM; Pillay A; Kanavos PG
Soc Sci Med; 2019 Jan; 220():362-370. PubMed ID: 30513486
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature Review.
Moots RJ; Curiale C; Petersel D; Rolland C; Jones H; Mysler E
BioDrugs; 2018 Jun; 32(3):193-199. PubMed ID: 29790131
[TBL] [Abstract][Full Text] [Related]
26. Competition Between Biosimilars and Patented Biologics: Learning from European and Japanese Experience.
Bocquet F; Loubière A; Fusier I; Cordonnier AL; Paubel P
Pharmacoeconomics; 2016 Nov; 34(11):1173-1186. PubMed ID: 27412251
[TBL] [Abstract][Full Text] [Related]
27. Price Determinants of the Tendering Process for Pharmaceuticals in the Cyprus Market.
Petrou P; Talias MA
Value Health Reg Issues; 2015 Sep; 7():67-73. PubMed ID: 29698154
[TBL] [Abstract][Full Text] [Related]
28. [Opportunities and challenges of extrapolation for biosimilars].
Weise M; Wolff-Holz E
Z Gastroenterol; 2016 Nov; 54(11):1211-1216. PubMed ID: 27711947
[TBL] [Abstract][Full Text] [Related]
29. Biosimilars for the Management of Inflammatory Bowel Diseases: Economic Considerations.
Gulacsi L; Pentek M; Rencz F; Brodszky V; Baji P; Vegh Z; Gecse KB; Danese S; Peyrin-Biroulet L; Lakatos PL
Curr Med Chem; 2019; 26(2):259-269. PubMed ID: 28393687
[TBL] [Abstract][Full Text] [Related]
30. Value Assessment and Quantitative Benefit-Risk Modelling of Biosimilar Infliximab for Crohn's Disease.
Catt H; Bodger K; Kirkham JJ; Hughes DA
Pharmacoeconomics; 2019 Dec; 37(12):1509-1523. PubMed ID: 31372948
[TBL] [Abstract][Full Text] [Related]
31. Biosimilars: Practical Considerations for Pharmacists.
Stevenson JG; Popovian R; Jacobs I; Hurst S; Shane LG
Ann Pharmacother; 2017 Jul; 51(7):590-602. PubMed ID: 28176529
[TBL] [Abstract][Full Text] [Related]
32. Biosimilars: A Multidisciplinary Perspective.
Khraishi M; Stead D; Lukas M; Scotte F; Schmid H
Clin Ther; 2016 May; 38(5):1238-49. PubMed ID: 26988243
[TBL] [Abstract][Full Text] [Related]
33. Incentives for market penetration of biosimilars in Belgium and in five European countries.
Swartenbroekx N; Farfan-Portet ; Espín J; Gerkens S
J Pharm Belg; 2014 Dec; (4):36-46. PubMed ID: 25562926
[TBL] [Abstract][Full Text] [Related]
34. Biosimilars in the Treatment of Inflammatory Bowel Disease: Supporting Evidence in 2017.
Scott FI; Lichtenstein GR
Curr Treat Options Gastroenterol; 2018 Mar; 16(1):147-164. PubMed ID: 29492747
[TBL] [Abstract][Full Text] [Related]
35. Biosimilars: How Can Payers Get Long-Term Savings?
Mestre-Ferrandiz J; Towse A; Berdud M
Pharmacoeconomics; 2016 Jun; 34(6):609-16. PubMed ID: 26792791
[TBL] [Abstract][Full Text] [Related]
36. Efficacy, Safety and Immunogenicity of Biosimilars in Inflammatory Bowel Diseases: A Systematic Review.
Martelli L; Peyrin-Biroulet L
Curr Med Chem; 2019; 26(2):270-279. PubMed ID: 27758715
[TBL] [Abstract][Full Text] [Related]
37. Biosimilars in the USA: Will New Efforts to Spur Approvals and Access Spur Uptake and Cost Savings?
Mehr SR; Brook RA
Pharmaceut Med; 2019 Feb; 33(1):1-8. PubMed ID: 31933270
[TBL] [Abstract][Full Text] [Related]
38. The Concept of Biosimilars: From Characterization to Evolution-A Narrative Review.
Farhat F; Torres A; Park W; de Lima Lopes G; Mudad R; Ikpeazu C; Abi Aad S
Oncologist; 2018 Mar; 23(3):346-352. PubMed ID: 29284760
[TBL] [Abstract][Full Text] [Related]
39. Competition in the off-patent medicine market in Spain: The national reference pricing system versus the regional system of tendering for outpatient prescription medicines in Andalusia.
Casanova-Juanes J; Mestre-Ferrandiz J; Espín-Balbino J
Health Policy; 2018 Dec; 122(12):1310-1315. PubMed ID: 30389186
[TBL] [Abstract][Full Text] [Related]
40. Physicians' perceptions of the uptake of biosimilars: a systematic review.
Sarnola K; Merikoski M; Jyrkkä J; Hämeen-Anttila K
BMJ Open; 2020 May; 10(5):e034183. PubMed ID: 32371511
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]